Core Viewpoint - Haiprime is a leading multinational pharmaceutical company with a focus on heparin, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a strong overseas revenue stream [2][3]. Company Overview - Established in 1998 in Shenzhen, Haiprime operates with both A and H share financing platforms, primarily engaged in the heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization [2]. - The company's main business revenue composition includes: 63.06% from formulations, 18.59% from CDMO, 16.05% from heparin sodium and low molecular weight heparin raw materials, and 2.30% from other sources [7]. Financial Performance - For the first half of 2025, Haiprime reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit attributable to shareholders of 422 million yuan, down 36.44% year-on-year [7]. - As of June 30, 2025, the company had a total market capitalization of 17.153 billion yuan, with a trading volume of 35.1323 million yuan on October 20, 2023 [1][7]. Market Position - Haiprime's overseas revenue accounted for 93.04% of its total revenue, benefiting from the depreciation of the RMB [3]. - The company is positioned within the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and chemical preparations [7]. Shareholder Information - As of June 30, 2025, Haiprime had 26,300 shareholders, a decrease of 7.29% from the previous period, with an average of 0 shares per shareholder [7]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 6.3765 million shares to 11.3176 million shares [9]. Dividend Distribution - Since its A-share listing, Haiprime has distributed a total of 4.21 billion yuan in dividends, with 514 million yuan distributed over the past three years [8].

Core Viewpoint - The company, Haiprui (09989.HK), has scheduled a board meeting on October 30, 2025, to consider and approve its third-quarter performance for the nine months ending September 30, 2025 [1] Summary by Relevant Categories - **Company Performance** - The board meeting will focus on the financial results for the third quarter of the fiscal year ending September 30, 2025 [1]

深圳市海普瑞藥業集團股份有限公司（「本公司」，連同其附屬公司，「本集團」）董 事會（「董事會」）兹通告，本公司謹定於二零二五年十月三十日（星期四）舉行董事 會會議，以考慮及通過本集團截至二零二五年九月三十日止九個月的第三季度業 績及其刊發。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. （深圳市海普瑞藥業集團股份有限公司） （於中華人民共和國註冊成立的股份有限公司） （股份代號：9989） 董事會會議召開日期 二零二五年十月十七日 於本公告日期，本公司執行董事為李鋰先生、李坦女士、單宇先生及張平先生； 本公司獨立非執行董事為呂川博士、黃鵬先生及易銘先生。 承董事會命 深圳市海普瑞藥業集團股份有限公司 李鋰 董事長 中國深圳 ...

Core Viewpoint - The company, Haiprui, is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a significant overseas revenue share [2][3]. Company Overview - Haiprui was established in 1998 in Shenzhen and has both A and H share financing platforms [2]. - The main business segments include heparin raw materials, low molecular weight heparin products, and biopharmaceutical CDMO services [7]. - As of June 30, 2025, the company reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit of 422 million yuan, down 36.44% year-on-year [7]. Financial Performance - The overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed in the last three years [8]. Market Activity - On October 16, Haiprui's stock price decreased by 0.17%, with a trading volume of 45.1938 million yuan and a turnover rate of 0.31%, resulting in a total market capitalization of 17.299 billion yuan [1]. - The stock's average trading cost is 11.57 yuan, with current price fluctuations between resistance at 12.33 yuan and support at 11.16 yuan [6]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 7.29% to 26,300, with no circulating shares per person [7]. - The eighth largest shareholder is Hong Kong Central Clearing Limited, holding 11.3176 million shares, an increase of 6.3765 million shares from the previous period [9].

Core Viewpoint - The stock of Haiprui has shown a mixed performance in recent trading sessions, with a year-to-date increase of 13.12% but a decline in the last five, twenty, and sixty days [1][2]. Company Overview - Haiprui Pharmaceutical Group Co., Ltd. is located in Nanshan District, Shenzhen, Guangdong Province, and was established on April 21, 1998. The company was listed on May 6, 2010 [1]. - The main business activities include research, production, and sales of heparin sodium raw materials and downstream low molecular weight heparin products. The revenue composition is as follows: formulations 63.06%, CDMO 18.59%, heparin sodium and low molecular weight heparin raw materials 16.05%, and others 2.30% [1]. Financial Performance - As of June 30, 2025, Haiprui reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%. The net profit attributable to shareholders was 422 million yuan, down 36.44% year-on-year [2]. - Cumulative cash dividends since the A-share listing amount to 4.21 billion yuan, with 514 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 7.29% to 26,300, with an average of 0 circulating shares per person [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 11.3176 million shares, an increase of 6.3765 million shares compared to the previous period [3].

Core Viewpoint - The company, Haiprui, is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a significant overseas revenue share [2][3]. Company Overview - Haiprui was established in 1998 in Shenzhen and has both A and H share financing platforms [2]. - The main business segments include heparin raw materials, downstream low molecular weight heparin products, and CDMO services for biopharmaceuticals [7]. - As of June 30, 2025, Haiprui reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit of 422 million yuan, down 36.44% year-on-year [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The average trading cost of the stock is 11.57 yuan, with the current stock price fluctuating between resistance at 12.33 yuan and support at 11.16 yuan [6]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 7.29% to 26,300 [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Activity - On October 14, Haiprui's stock fell by 1.53%, with a trading volume of 59.5826 million yuan and a turnover rate of 0.41%, resulting in a total market capitalization of 16.962 billion yuan [1].

Core Viewpoint - The company Haiprui experienced a decline of 1.68% in stock price, with a trading volume of 47.80 million yuan and a total market capitalization of 17.23 billion yuan [1] Company Overview - Haiprui, established in 1998 in Shenzhen, is a leading multinational pharmaceutical company with A+H dual financing platforms, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization [2][7] - The main business revenue composition includes formulations (63.06%), CDMO (18.59%), heparin sodium and low molecular weight heparin raw materials (16.05%), and others (2.30%) [7] Financial Performance - For the first half of 2025, Haiprui reported a revenue of 2.82 billion yuan, a year-on-year decrease of 0.71%, and a net profit attributable to shareholders of 422 million yuan, down 36.44% year-on-year [7] - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8] Market Position and Trends - As of the 2024 annual report, overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the yuan [3] - The company operates in the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and chemical preparations, with concepts including raw materials, heparin, biopharmaceuticals, innovative drugs, and vaccines [7] Institutional Holdings - As of June 30, 2025, the eighth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 11.32 million shares, an increase of 6.38 million shares from the previous period [9]

FF301 致：香港交易及結算所有限公司 公司名稱: 深圳市海普瑞藥業集團股份有限公司 呈交日期: 2025年10月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09989 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 220,094,500 | RMB | | 1 RMB | | 220,094,500 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 220,094,500 | RMB | | 1 RMB | | 220,094,500 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- ...

Core Viewpoint - The company, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., is a leading multinational pharmaceutical enterprise with a focus on heparin, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a strong overseas revenue stream [2][3]. Company Overview - Established in 1998 and listed in 2010, Hepalink operates primarily in the heparin industry, with its main business segments including formulations (63.06%), CDMO (18.59%), and heparin raw materials (16.05%) [7]. - As of June 30, 2025, the company reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit of 422 million yuan, down 36.44% year-on-year [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The total market capitalization of Hepalink is 17.666 billion yuan, with a trading volume of 37.9727 million yuan on September 25, 2023 [1]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 7.29% to 26,300, with the average circulating shares per person remaining at zero [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Activity - On September 25, 2023, the stock price of Hepalink fell by 1.15%, with a turnover rate of 0.25% [1]. - The stock is currently near a resistance level of 12.33 yuan, with an average trading cost of 11.57 yuan [6].

Core Viewpoint - The recent trading activity and financial performance of Haiprui Pharmaceutical indicate a mixed outlook, with notable fluctuations in financing and stockholder dynamics [1][2]. Financing Activity - On September 24, Haiprui's stock rose by 1.16%, with a trading volume of 41.77 million yuan. The financing buy-in amounted to 4.87 million yuan, while the financing repayment was 5.70 million yuan, resulting in a net financing outflow of 0.83 million yuan [1]. - As of September 24, the total financing and securities lending balance for Haiprui was 258 million yuan, with the financing balance of 256 million yuan accounting for 1.69% of the circulating market value, which is above the 60th percentile of the past year [1]. - In terms of securities lending, Haiprui repaid 6,200 shares and sold 8,500 shares on the same day, with a selling amount of 0.1035 million yuan. The remaining securities lending volume was 10,840 shares, with a balance of 1.32 million yuan, exceeding the 90th percentile of the past year [1]. Financial Performance - For the first half of 2025, Haiprui reported a revenue of 2.817 billion yuan, reflecting a year-on-year decrease of 0.71%. The net profit attributable to shareholders was 422 million yuan, down 36.44% year-on-year [2]. - Since its A-share listing, Haiprui has distributed a total of 4.21 billion yuan in dividends, with 514 million yuan distributed over the past three years [2]. Shareholder Dynamics - As of June 30, 2025, Haiprui had 26,300 shareholders, a decrease of 7.29% from the previous period. The average circulating shares per shareholder remained at 0 [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited ranked as the eighth largest, holding 11.32 million shares, an increase of 6.38 million shares from the previous period [2].